Cabaletta Bio, Inc. (CABA)Healthcare | Biotechnology | Philadelphia, United States | NasdaqGS
1.69 USD
-0.10
(-5.587%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 1.67 -0.02 (-0.019%) ⇩ (Oct. 13, 2026, 6:31 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 4:27 a.m. EDT
The investment case here is severely compromised by a deteriorating business trajectory and overwhelming speculative fear. Fundamentally, the company is burning cash with negative free cash flow and negative returns on equity, trading at a loss with no dividend to offset the capital destruction. The price history confirms this pain, showing a catastrophic collapse from a peak of $16.50 in 2023 to roughly $2.30 in 2025, followed by two consecutive years of decline. While recent news headlines cite positive early trial results, the market has already priced in a massive correction, leaving the stock vulnerable to further disappointment if commercialization timelines slip. Technically, the stock is trapped between heavy resistance and a lack of buying power, having failed to reclaim key moving averages. The options chain tells the most damning story: traders are not betting on a recovery; they are buying deep out-of-the-money puts to bet against the stock, creating a dense wall of resistance that will likely keep prices suppressed. With a beta of 3.47, any minor negative catalyst could trigger a disproportionate sell-off. There is no margin of safety here; the balance sheet is strained, and the path to profitability remains unclear. This is a high-risk speculative vehicle for aggressive traders, not a viable long-term investment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.103981 |
| AutoARIMA | 0.104551 |
| MSTL | 0.106604 |
| AutoTheta | 0.154482 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 31.52 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.393 |
| Excess Kurtosis | 0.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.21 |
| Market Cap | 286,531,808 |
| Forward P/E | -1.42 |
| Beta | 3.48 |
| Website | https://www.cabalettabio.com |
As of Oct. 10, 2026, 4:27 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive open interest and volume in out-of-the-money puts (strikes $4.00, $4.50, $5.00) expiring late in 2026 and throughout 2027. Call activity is negligible and concentrated near the money, while put writers are accumulating significant exposure at strikes significantly above the current price, suggesting a consensus expectation of further weakness rather than a rebound.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.38062286 |
| Address1 | 2,929 Arch Street |
| Address2 | Suite 600 |
| All Time High | 26.35 |
| All Time Low | 0.59 |
| Ask | 2.06 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 5,152,430 |
| Average Daily Volume3 Month | 4,615,009 |
| Average Volume | 4,615,009 |
| Average Volume10Days | 5,152,430 |
| Beta | 3.475 |
| Bid | 1.29 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 1.256 |
| City | Philadelphia |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.69 |
| Current Ratio | 5.789 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.82 |
| Day Low | 1.59 |
| Debt To Equity | 12.21 |
| Display Name | Cabaletta Bio |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,832,200 |
| Earnings Timestamp Start | 1,794,832,200 |
| Ebitda | -184,115,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.565 |
| Enterprise Value | 104,098,344 |
| Eps Current Year | -1.35584 |
| Eps Forward | -1.18963 |
| Eps Trailing Twelve Months | -1.51 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.671 |
| Fifty Day Average Change | -0.98099995 |
| Fifty Day Average Change Percent | -0.36727816 |
| Fifty Two Week Change Percent | -38.062286 |
| Fifty Two Week High | 4.23 |
| Fifty Two Week High Change | -2.54 |
| Fifty Two Week High Change Percent | -0.6004728 |
| Fifty Two Week Low | 1.59 |
| Fifty Two Week Low Change | 0.100000024 |
| Fifty Two Week Low Change Percent | 0.06289309 |
| Fifty Two Week Range | 1.59 - 4.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,572,010,200,000 |
| Float Shares | 141,483,978 |
| Forward Eps | -1.18963 |
| Forward P E | -1.4206098 |
| Free Cashflow | -98,343,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 154 |
| Fullday Change | -0.119399905 |
| Fullday Change Percent | -6.6703863 |
| Fullday Price | 1.6706 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0096700005 |
| Held Percent Institutions | 0.94416 |
| Implied Shares Outstanding | 169,545,445 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. |
| Long Name | Cabaletta Bio, Inc. |
| Market | us_market |
| Market Cap | 286,531,808 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_590735322 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -181,318,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 373,847,706 |
| Number Of Analyst Opinions | 8 |
| Open | 1.82 |
| Operating Cashflow | -153,927,008 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Phone | 267 759 3100 |
| Post Market Change | -0.0194 |
| Post Market Change Percent | -1.147929 |
| Post Market Price | 1.6706 |
| Post Market Time | 1,791,930,701 |
| Previous Close | 1.79 |
| Price Eps Current Year | -1.2464598 |
| Price Hint | 4 |
| Price To Book | 1.3455414 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.64 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.099999905 |
| Regular Market Change Percent | -5.586587 |
| Regular Market Day High | 1.82 |
| Regular Market Day Low | 1.59 |
| Regular Market Day Range | 1.59 - 1.82 |
| Regular Market Open | 1.82 |
| Regular Market Previous Close | 1.79 |
| Regular Market Price | 1.69 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 7,933,759 |
| Return On Assets | -0.48188 |
| Return On Equity | -0.93205 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 169,545,445 |
| Shares Percent Shares Out | 0.22770001 |
| Shares Short | 38,613,761 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 41,442,251 |
| Short Name | Cabaletta Bio, Inc. |
| Short Percent Of Float | 0.2511 |
| Short Ratio | 6.26 |
| Source Interval | 15 |
| State | PA |
| Symbol | CABA |
| Target High Price | 30.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 13.25 |
| Target Median Price | 13.5 |
| Total Cash | 225,100,992 |
| Total Cash Per Share | 1.328 |
| Total Debt | 25,713,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.51 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.90125 |
| Two Hundred Day Average Change | -1.2112498 |
| Two Hundred Day Average Change Percent | -0.41749242 |
| Type Disp | Equity |
| Volume | 7,933,759 |
| Website | https://www.cabalettabio.com |
| Zip | 19,104 |